Dawson James Begins Coverage on Bluejay Diagnostics (NASDAQ:BJDX)

Dawson James started coverage on shares of Bluejay Diagnostics (NASDAQ:BJDX) in a research note released on Wednesday morning, The Fly reports. The firm issued a buy rating and a $10.00 price objective on the stock.

Shares of BJDX opened at $2.66 on Wednesday. Bluejay Diagnostics has a 1 year low of $2.22 and a 1 year high of $6.25. The company’s fifty day moving average price is $2.96.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings results on Thursday, December 16th. The company reported ($0.11) earnings per share (EPS) for the quarter.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics Inc is a late-stage, pre-revenue medical device company. It focused on developing near-patient products for triage, diagnosis and monitoring of disease progression. Bluejay Diagnostics Inc is based in ACTON, Mass.

Recommended Story: Return On Assets

The Fly logo

Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.